The estimated Net Worth of Jay S Skyler is at least $32.1 million dollars as of 22 June 2021. Jay Skyler owns over 20,000 units of Dexcom Inc stock worth over $956,389 and over the last 20 years he sold DXCM stock worth over $30,812,137. In addition, he makes $331,025 as Independent Director at Dexcom Inc.
Jay has made over 22 trades of the Dexcom Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of DXCM stock worth $8,527,400 on 22 June 2021.
The largest trade he's ever made was buying 70,000 units of Dexcom Inc stock on 11 March 2013 worth over $1,085,000. On average, Jay trades about 9,841 units every 92 days since 2005. As of 22 June 2021 he still owns at least 13,968 units of Dexcom Inc stock.
You can see the complete history of Jay Skyler stock trades at the bottom of the page.
Dr. Jay S. Skyler M.D. serves as Independent Director of the Company. He has served on our Board since September 2002. Dr. Skyler is a Professor of Medicine, Pediatrics and Psychology and Deputy Director of the Diabetes Research Institute at the University of Miami in Florida, where he has been employed since 1976. For 22 years, Dr. Skyler also served as Study Chairman for the National Institute of Diabetes & Digestive & Kidney Diseases Type 1 Diabetes clinical trials network. He is a past President of the American Diabetes Association and a past Vice-President of the International Diabetes Federation. Dr. Skyler served as a director of Amylin Pharmaceuticals, Inc. until its acquisition by Bristol-Myers Squibb Company in August 2012, and served as a director of MiniMed, Inc. until its acquisition by Medtronic, Inc. in 2001. Dr. Skyler received a B.S. from Pennsylvania State University and an M.D. from Jefferson Medical College.
As the Independent Director of Dexcom Inc, the total compensation of Jay Skyler at Dexcom Inc is $331,025. There are 11 executives at Dexcom Inc getting paid more, with Kevin Sayer having the highest compensation of $10,279,400.
Jay Skyler is 73, he's been the Independent Director of Dexcom Inc since 2002. There are no older and 28 younger executives at Dexcom Inc.
Jay's mailing address filed with the SEC is C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY, 10017.
Over the last 20 years, insiders at Dexcom Inc have traded over $724,717,982 worth of Dexcom Inc stock and bought 165,450 units worth $3,489,100 . The most active insiders traders include Sean Carney, Kim D Blickenstaff et Steven R Altman. On average, Dexcom Inc executives and independent directors trade stock every 7 days with the average trade being worth of $892,438. The most recent stock trade was executed by Sadie Stern on 9 September 2024, trading 426 units of DXCM stock currently worth $29,458.
founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.
Dexcom Inc executives and other stock owners filed with the SEC include: